

# Activation of sodium-proton exchange is not a prerequisite for $\text{Ca}^{2+}$ mobilization and aggregation in human platelets

László Hunyady, Balázs Sarkadi\*, Edward J. Cragoe, jr<sup>+</sup>, András Spät and George Gárdos\*

*Department of Physiology, Semmelweis University of Medicine, Puskin u. 9, PO Box 259, H-1444 Budapest 8, \*National Institute of Haematology and Blood Transfusion, H-1113 Budapest, Hungary and <sup>+</sup>Merck Sharp & Dohme Research Laboratories, West Point, PA 19486, USA*

Received 21 October 1987

Recently it has been suggested [(1987) *Nature* 325, 456–458; (1987) *FEBS Lett.* 212, 123–126] that the activation of  $\text{Na}^+/\text{H}^+$  exchange is a prerequisite for platelet aggregation and the development of the  $\text{Ca}^{2+}$  signal. As direct evidence for the role of the  $\text{Na}^+/\text{H}^+$ -exchange pathway the inhibition of the  $\text{Ca}^{2+}$  signal by EIPA, a specific inhibitor of  $\text{Na}^+/\text{H}^+$  exchange, was offered. Here we demonstrate that low concentrations of EIPA (below  $1\ \mu\text{M}$ ) completely block  $\text{Na}^+/\text{H}^+$  exchange while EIPA inhibits aggregation or  $\text{Ca}^{2+}$  mobilization only in concentrations 100-times greater than  $1\ \mu\text{M}$ . Moreover, another amiloride analogue, CBDMB, developed to act predominantly on  $\text{Na}^+/\text{Ca}^{2+}$  exchange, does not affect  $\text{Na}^+/\text{H}^+$  exchange in platelets but blocks aggregation and  $\text{Ca}^{2+}$  mobilization. We conclude that while  $\text{Na}^+/\text{H}^+$  exchange has a fundamental role in platelet functions it is not prerequisite for the development of  $\text{Ca}^{2+}$  signal and aggregation.

$\text{Ca}^{2+}$  signal;  $\text{Na}^+/\text{H}^+$  exchange; Thrombin; Amiloride analogue; (Human platelet)

## 1. INTRODUCTION

By now it is generally accepted that cell activation by a variety of stimulating agents is mediated by a rapid rise in  $[\text{Ca}^{2+}]_i$  and involves the specific hydrolysis of phosphatidylinositol 4,5-bisphosphate to yield  $\text{InsP}_3$  and DAG.  $\text{InsP}_3$  liberates  $\text{Ca}^{2+}$  from a non-mitochondrial intracellular store while DAG may act through the activation of protein kinase C which, in turn, can activate  $\text{Na}^+/\text{H}^+$

exchange in the plasma membrane [3–7]. The actual timing of all these intracellular events is still poorly understood and platelets provide a relatively well manageable model system for studying these phenomena. Several studies in platelets have indicated that a thrombin-induced  $\text{Ca}^{2+}$  signal precedes the activation of  $\text{Na}^+/\text{H}^+$  exchange [8–10]. However, in their recent communications Siffert et al. [1,2] concluded that the activation of sodium-proton exchange is a prerequisite for  $\text{Ca}^{2+}$  mobilization and aggregation in human platelets. They showed that removal of external  $\text{Na}^+$  strongly reduced the thrombin-induced increase in  $[\text{Ca}^{2+}]_i$  as measured in quin2-loaded platelets, both in the presence or absence of external  $\text{Ca}^{2+}$ . An amiloride analogue, EIPA, inhibitor of the  $\text{Na}^+/\text{H}^+$ -exchange transport, also inhibited this  $\text{Ca}^{2+}$  signal, while the resting  $[\text{Ca}^{2+}]_i$  was unchanged. The authors further showed that removal of  $\text{Na}^+$  inhibited  $\text{H}^+$  extrusion, while intracellular

Correspondence address: L. Hunyady, Dept of Physiology, Semmelweis University of Medicine, Puskin u. 9, PO Box 259, H-1444 Budapest 8, Hungary

*Abbreviations:*  $[\text{Ca}^{2+}]_i$ , cytoplasmic free  $\text{Ca}^{2+}$  concentration; CBDMB, 5-(*N*-4-chlorobenzyl)-*N*-(2',4'-dimethyl)benzamil; DMB, *N*-(2',4'-dimethyl)benzamil; EIPA, 5-(*N*-ethyl-*N*-isopropyl)amiloride;  $\text{InsP}_3$ , inositol 1,4,5-trisphosphate; DAG, 1,2-diacylglycerol

alkalinization potentiated the thrombin-induced  $\text{Ca}^{2+}$  signal and platelet aggregation. Moreover, thrombin induced an intracellular alkaline shift and this was prevented by the removal of external  $\text{Na}^+$  or by the addition of EIPA.

The only direct evidence for the role of the  $\text{Na}^+/\text{H}^+$ -exchange pathway in  $\text{Ca}^{2+}$  mobilization is the inhibition of the  $\text{Ca}^{2+}$  signal by EIPA in quin2-loaded platelets. However, in these experiments [1,2] the authors used 40–100  $\mu\text{M}$  of this inhibitor, while the half-maximal inhibitory concentration of EIPA on  $\text{Na}^+/\text{H}^+$  exchange, as measured in a variety of tissues at physiological  $\text{Na}^+$  concentrations, is about 0.1  $\mu\text{M}$  [11–14]. Thus a non-specific effect of this amiloride analogue in these high concentrations may occur.

In order to resolve these questions we have measured the concentration-dependent effects of EIPA and another amiloride analogue, CBDMB, on  $\text{Ca}^{2+}$  mobilization, aggregation and on  $\text{Na}^+/\text{H}^+$  exchange as reflected by a Na-propionate-induced swelling in human platelets. The amiloride analogue CBDMB was developed to act predominantly on  $\text{Na}^+/\text{Ca}^{2+}$  exchange, because as a consequence of substitution of the guanidino group of amiloride it has a negligible effect on  $\text{Na}^+/\text{H}^+$  exchange ( $K_i$  above 500  $\mu\text{M}$ ) [13–15], while its  $K_i$  for  $\text{Na}^+/\text{Ca}^{2+}$  exchange is 7.3  $\mu\text{M}$  as demonstrated on pituitary plasma membrane vesicles using the method described in [16] (Kaczorowski, G.J., personal communication).

## 2. MATERIALS AND METHODS

Platelets were isolated from freshly drawn citrated blood by centrifugation at  $400 \times g$  for 10 min. Platelet-rich plasma was centrifuged for 15 min at  $1200 \times g$  and the platelets were resuspended in a nominally  $\text{Ca}^{2+}$ -free Tyrode solution (pH 7.25). Platelets were loaded with quin2 by incubating them in the same solution containing 15  $\mu\text{M}$  quin2-acetoxymethyl ester (Calbiochem) for at least 30 min at room temperature. Then the cells were centrifuged for 10 s at  $10000 \times g$ , rinsed twice and resuspended ( $10^8$  cells/ml) in the same solution. Fluorescence was measured by a Hitachi F-4000 fluorescent spectrophotometer at  $37^\circ\text{C}$  with continuous stirring. Fluorescence was recorded at an excitation wavelength of 337 nm (5 nm

slit) and an emission wavelength of 490 nm (5 nm slit). Calibration of  $[\text{Ca}^{2+}]_i$  was carried out as described in [17,18] using an apparent  $K_d$  of 115 nM for  $\text{Ca}^{2+}$ -quin2 (cf. [17]). CBDMB gave a concentration-dependent background fluorescence independent of divalent cations or thrombin and this fluorescence has been subtracted. Aggregation was measured in the same quin2-loaded cells in the presence of 1% plasma in a Lumi-aggregometer (Chrono-log, model 460, PICA), at  $37^\circ\text{C}$ . EIPA, DMB and CBDMB were synthesised by the methods described [19,20].

For measuring  $\text{Na}^+/\text{H}^+$  exchange quin2-loaded or control platelets were suspended at 0 min in a Na-propionate medium (140 mM Na-propionate, 1 mM  $\text{CaCl}_2$ , 2 mM  $\text{MgCl}_2$ , 5.5 mM glucose, 20 mM Tris-HCl, pH 6.8). Cell volume was measured by an electronic sizing (Coulter-type) instrument (Laborscale, Medicor). Cell volume was calibrated by latex beads. There was no difference observed in this experiment between control or quin2-loaded platelets.

## 3. RESULTS AND DISCUSSION

### 3.1. *Effects of EIPA and CBDMB on $\text{Ca}^{2+}$ signal and aggregation*

Fig.1 demonstrates the effects of EIPA and CBDMB on the thrombin-induced increase in  $[\text{Ca}^{2+}]_i$  in quin2-loaded human platelets. Up to 10  $\mu\text{M}$  concentration EIPA has no effect on aggregation or on the  $\text{Ca}^{2+}$  signal. It was previously reported by Siffert et al. [21] and others [10] that EIPA at this concentration (10  $\mu\text{M}$ ) almost completely abolishes thrombin-induced alkalinization. As shown in fig.1, 10  $\mu\text{M}$  CBDMB or 40  $\mu\text{M}$  EIPA inhibit the  $\text{Ca}^{2+}$  signal and aggregation. By a detailed analysis of these effects we found that half-maximum inhibition was obtained by about 30  $\mu\text{M}$  EIPA and 3–5  $\mu\text{M}$  CBDMB. Both EIPA and CBDMB had the above concentration-dependent effects on the thrombin-induced rise of  $[\text{Ca}^{2+}]_i$  in quin2-loaded platelets in the absence of external  $\text{Ca}^{2+}$  as well (not shown). It has to be mentioned that 10  $\mu\text{M}$  CBDMB, in the presence of 1 mM external  $\text{Ca}^{2+}$ , produced a slow rise in platelet  $[\text{Ca}^{2+}]_i$  (fig.1). This effect was independent of the addition of thrombin (not shown) and caused a delayed, non-specific, slow aggregation.




Fig.1. Effects of EIPA and CBDMB on the thrombin-induced increase in  $[Ca^{2+}]_i$  (upper panel) and aggregation (lower panel) in human platelets loaded with the fluorescent  $Ca^{2+}$  indicator quin2. (A) Control; (B) 10  $\mu$ M EIPA; (C) 40  $\mu$ M EIPA; (D) 10  $\mu$ M CBDMB. The arrows indicate the addition of  $CaCl_2$  (final conc. 1 mM) and thrombin (0.5 U/ml). Each trace represents experiments repeated with three or four different preparations.

### 3.2. Effects of EIPA and CBDMB on $Na^+/H^+$ exchange

Fig.2 shows the effects of EIPA and CBDMB on  $Na^+/H^+$  exchange in human platelets. It was studied by using a simple test-system: swelling in a Na-propionate medium. This method has been used in various cell types to follow the functioning of the  $Na^+/H^+$ -exchange system [22–25] as in a Na-propionate medium undissociated propionic

acid enters the cells and cytoplasmic acidification initiates  $Na^+/H^+$  exchange. These processes result in net  $Na^+$  and propionate entry and cell swelling. The increase in cell volume can be followed by electronic sizing and any inhibitor of  $Na^+/H^+$  exchange stops this swelling [23–25]. This swelling can only occur if a coupled  $Na^+/H^+$  exchange is in operation and, as shown in fig.2, is strongly inhibited by low concentrations of EIPA. Based on




Fig.2. Effects of EIPA and CBDMB on  $\text{Na}^+/\text{H}^+$  exchange as measured by platelet swelling in a Na-propionate medium. Results are representative of four independent experiments. (A) Control; (B)  $10 \mu\text{M}$  CBDMB; (C)  $0.1 \mu\text{M}$  EIPA; (D)  $2 \mu\text{M}$  EIPA; (E)  $10 \mu\text{M}$  EIPA.

four different experiments the half-maximal inhibition was obtained between  $0.1$  and  $0.2 \mu\text{M}$  EIPA, in good agreement with the data for the inhibition of  $\text{Na}^+/\text{H}^+$  exchange in other tissues [11–14]. CBDMB was found to be ineffective on  $\text{Na}^+/\text{H}^+$  exchange-dependent platelet swelling up to the concentration of  $10 \mu\text{M}$  (higher concentrations produced platelet degradation).

Another amiloride analogue, DMB, specific for inhibition of  $\text{Na}^+/\text{Ca}^{2+}$  exchange in different tissues [16] acted similarly to CBDMB (not shown).

#### 4. CONCLUSIONS

From the above experimental findings we conclude that EIPA inhibits  $\text{Ca}^{2+}$  mobilization and aggregation of human platelets only in concentrations more than 100-times greater than that required to block  $\text{Na}^+/\text{H}^+$  exchange. In contrast the amiloride analogue CBDMB, presumed to act dominantly on  $\text{Na}^+/\text{Ca}^{2+}$  exchange, inhibits the signal and aggregation without any effect on the  $\text{Na}^+/\text{H}^+$ -exchange system. Certainly, the inhibition of  $\text{Na}^+/\text{H}^+$  exchange does not prevent ag-

gregation and  $\text{Ca}^{2+}$  mobilization, thus the activation of  $\text{Na}^+/\text{H}^+$  exchange is not a prerequisite for these processes. The modulating effects of external  $\text{Na}^+$  and the inhibition of platelet activation by amiloride derivatives may indicate a certain role for  $\text{Na}^+/\text{Ca}^{2+}$  exchange or other, as yet unidentified  $\text{Na}^+$ -dependent processes.

#### ACKNOWLEDGEMENTS

We wish to thank for the helpful discussions with Drs M. Szirmai and I. Szász and for the technical assistance of Mrs S. Andrásí and M. Sarkadi.

#### REFERENCES

- [1] Siffert, W. and Akkerman, J.W.N. (1987) *Nature* 325, 456–458.
- [2] Siffert, W., Siffert, G., Scheid, P., Riemens, T., Gorter, G. and Akkerman, J.W.N. (1987) *FEBS Lett.* 212, 123–126.
- [3] Berridge, M.J. (1986) *J. Exp. Biol.* 124, 323–335.
- [4] Hokin, L.E. (1985) *Annu. Rev. Biochem.* 54, 205–235.
- [5] Irvine, R.F. (1986) *Br. Med. Bull.* 42, 369–374.
- [6] Nishizuka, Y. (1986) *Science* 233, 305–312.
- [7] Moolenaar, W.H. (1986) *Annu. Rev. Physiol.* 48, 363–376.
- [8] Sage, S.O. and Rink, T.J. (1986) *Eur. J. Pharmacol.* 128, 99–107.
- [9] Sweatt, J.D., Connolly, T.M., Cragoe, E.J. jr and Limbird, L.E. (1986) *J. Biol. Chem.* 261, 8667–8673.
- [10] Zavoico, G.B., Cragoe, E.J. jr and Feinstein, M.B. (1986) *J. Biol. Chem.* 261, 13160–13167.
- [11] Vigne, P., Frelin, C., Cragoe, E.J. jr and Lazdunski, M. (1983) *Biochem. Biophys. Res. Commun.* 116, 86–90.
- [12] Frelin, C., Vigne, P. and Lazdunski, M. (1984) *J. Biol. Chem.* 259, 8880–8885.
- [13] Zhuang, Y.-X., Cragoe, E.J. jr, Shaikewitz, T., Glaser, L. and Cassel, D. (1984) *Biochemistry* 23, 4481–4488.
- [14] Lazdunski, M., Frelin, C. and Vigne, P. (1985) *J. Mol. Cell. Cardiol.* 17, 1029–1042.
- [15] Simchowicz, L. and Cragoe, E.J. jr (1986) *Mol. Pharmacol.* 30, 112–120.
- [16] Kaczorowski, G.J., Barros, F., Dethmers, J.K., Trumble, M.J. and Cragoe, E.J. jr (1985) *Biochemistry* 24, 1394–1403.

- [17] Rink, T.J. and Pozzan, T. (1985) *Cell Calcium* 6, 133–144.
- [18] Hesketh, T.R., Smith, G.A., Moore, J.P., Taylor, M.V. and Metcalfe, J.C. (1983) *J. Biol. Chem.* 258, 4876–4882.
- [19] Cragoe, E.J. jr, Woltersdorf, O.W. and DeSolms, S.J. (1981) US Patent 4, 246, 406.
- [20] Cragoe, E.J. jr, Woltersdorf, O.W. jr, Bicking, J.B., Kwong, S.F. and Jones, J.H. (1967) *J. Med. Chem.* 10, 66–75.
- [21] Siffert, W., Siffert, G. and Scheid, P. (1987) *Biochem. J.* 241, 301–303.
- [22] Roos, A. and Boron, W.F. (1981) *Physiol. Rev.* 61, 296–434.
- [23] Grinstein, S., Goetz, J.D., Furuya, W., Rothstein, A. and Gelfand, E.W. (1984) *Am. J. Physiol.* 247, C293–C298.
- [24] Sarkadi, B., Attisano, L., Grinstein, S., Buchwald, M. and Rothstein, A. (1984) *Biochim. Biophys. Acta* 774, 159–168.
- [25] Szirmai, M., Sarkadi, B., Szász, I. and Gárdos, G. (1987) *Haematologia*, in press.